uvstocks.io

Today’s CSR movers

SRE 4.1 ▲ 1.2

ES 3.0 ▲ 0.8

EIX 3.1 ▲ 0.8

AMZN 4.7 ▲ 0.1

GS 2.3 ▼ 0.8

WEC 2.6 ▼ 1.2

ETR 2.9 ▼ 1.2

C 2.8 ▼ 1.2

PCG 2.9 ▼ 1.2

FOX 2.4 ▼ 1.5

Health Care · NASDAQ NASDAQ · BIIB

Biogen

$199.95 -$5.86 -2.93% CLOSE 07.20.26 AFTER HOURS $199.02

Convergence score

4.0 / 5.0 STRONG BULLISH

+0.0 vs last report

Overall valuation

Undervalued

Aggregated across multiple horizons

Consensus target (12mo)

$224.44 +12.2%

Range $157.00 — $300.00

Sector

Health Care

NASDAQ · Tracked daily

Today's snapshot

Where the signals stand.

REPORT 07.20.26

UV Convergence Score

REPORT 07.20.26

4.0

/ 5.0

STRONG BULLISH

Consensus signal A

4.0

Consensus signal B

4.0

Consensus signal D

4.0

Rating trend signal

4.1

Analyst average

4.1

Multi-signal aggregate How CSR works →

Day Range

$199.62 – $205.65

52W Range

$121.05 – $219.72

Volume

896.5K

Avg Vol

1.3M

Mkt Cap

$29.52B

P/E

21.52

EPS (TTM)

$9.29

Div Yield

—

Beta

0.16

Today's convergence

Convergence score sits at 4.0 with overall valuation reading as undervalued. Drivers across the horizons inform the aggregate. Open the deep dives for valuation, analyst, or financial detail.

Valuation

Undervalued

CSR direction

STRONG BULLISH

Last close

$199.95

Sector

Health Care

Valuation

Three horizons

UPDATED 07.20.26

Short term

0–3 MO

No target Moderate Buy

Medium term

3–12 MO

$220+10.0% Buy

Long term

12–36 MO

$304.14+52.1% Undervalued

Open valuation →

Analysts

Coverage & consensus

4 PANELS

Mean target (12mo)

$224.44 +12.2%

RANGE $157.00 — $300.00

Analyst consensus

Consensus rating Buy

Blended score 4.1 / 5

Analysts tracked 131

Open analysts →

Financials

Key metrics

LATEST

P/E

21.52

EPS (TTM)

$9.29

Mkt Cap

$29.52B

Div Yield

—

Beta

0.16

52W Range

$121.05 – $219.72

Open financials →

Reports

Valuation breakdown

Three horizons, one consensus.

UPDATED 07.20.26

Short term

0–3 MO

Moderate Buy

Consensus target

No target available

Current analyst consensus rating from Barchart.

Medium term

3–12 MO

Buy

Consensus target

$220 +10.0%

RANGE $157 – $300

$157NOW $199.95$300

12-month analyst consensus target across covering brokerages.

Long term

12–36 MO

Undervalued

Consensus target

$304.14 +52.1%

UVStocks in-house sector-relative valuation model.

Signal breakdown

What’s driving the score.

EACH SIGNAL RATED 1.0 — 5.0

Top-level breakdown

Valuation:	PE Ratio: 21.52	PEG Ratio: -	DE Ratio: -
Free Cash Flow: $1.93B	PB Ratio: -	PS Ratio: -	Dividend: -

Analyst coverage

Blended analyst consensus & targets.

4 PANELS · UPDATED 07.20.26

Analyst consensus RATING · SCORE · PANELS · ANALYSTS

Rating Blended score Panels Analysts

Buy 4.1 4 131

Price targets LOW · MEAN · MEDIAN · HIGH · UPSIDE

Coverage Low Mean Median High Upside

All panels $157.00 $224.44 $225.00 $300.00 +12.2%

Rating distribution STRONG BUY · BUY · HOLD · SELL · STRONG SELL

Coverage SB B H S SS

All panels 4 36 23 3 0

Rating trend CURRENT VS 1M / 2M / 3M

Period Rating Avg Analysts

Current Moderate Buy 4.09 35

1 Mo Ago Moderate Buy 4.09 35

2 Mo Ago Moderate Buy 4.06 35

3 Mo Ago Moderate Buy 3.85 34

Most recent analyst action LATEST DESK ACTION

Date

7/14/2026

Firm

Piper Sandler

Action

Reiterated Rating

Rating

Overweight

Target

—

Full financial snapshot.

UPDATED 07.20.26

Quote snapshot 15 FIELDS

Prev Close

$205.99

Open

$204.08

Day Low

$199.62

Day High

$205.65

Bid

$193.34

Ask

$213.68

52W Low

$121.05

52W High

$219.72

50D Avg

$198.81

200D Avg

$180.74

Volume

896.5K

Avg Vol

1.3M

10D Avg Vol

1.8M

52W Change

67.91%

S&P 52W Change

18.27%

Valuation ratios 10 FIELDS

P/E (TTM)

21.52

P/E (Fwd)

12.09

PEG (Fwd)

4.34

P/S

2.97

P/B

1.58

Book Value

$126.37

EV/Revenue

3.20

EV/EBITDA

8.98

Mkt Cap

29.52B

Enterprise Val

31.8B

Profitability & returns 6 FIELDS

Profit Margin

13.81%

Gross Margin

78.72%

Operating Margin

22.90%

EBITDA Margin

35.62%

Return on Assets

5.95%

Return on Equity

7.70%

Growth 3 FIELDS

Revenue Growth (YoY)

1.90%

Earnings Growth (YoY)

31.10%

Earnings Growth (Q)

32.80%

Balance sheet & cash flow 11 FIELDS

Total Revenue

9.94B

EBITDA

3.54B

Total Cash

4.28B

Total Debt

6.56B

Cash / Share

$29.01

Revenue / Share

$67.70

Free Cash Flow

1.93B

Operating CF

2.59B

Debt / Equity

35.18

Current Ratio

3.06

Quick Ratio

2.02

Dividend 5 FIELDS

Fwd Dividend

—

Dividend Yield

—

Payout Ratio

0.00%

5Y Avg Yield

—

Ex-Div Date

—

Share statistics 7 FIELDS

Shares Out

147.64M

Float

147.18M

Shares Short

5.72M

% Short of Float

4.32%

Short Ratio

4.96

% Held Insiders

0.19%

% Held Institutions

96.31%

Calendar & events 5 FIELDS

Next Earnings

2026-07-29

Fiscal Year End

2025-12-31

Most Recent Qtr

2026-03-31

Last Split

3:1

Split Date

2001-01-18

Company 2 FIELDS

Industry

Drug Manufacturers - General

Employees

7,500